Semaglutide Therapy: Complete Guide

GLP-1 Receptor Agonism

Semaglutide works by binding to and activating GLP-1 receptors throughout the body. These receptors are found in multiple organ systems, which explains the peptide's wide-ranging physiological effects.

Pancreatic Effects

In the pancreas, semaglutide stimulates glucose-dependent insulin secretion from beta cells while simultaneously suppressing glucagon release from alpha cells. Crucially, this insulin-stimulating effect is glucose-dependent, meaning it primarily acts when blood sugar is elevated, significantly reducing the risk of hypoglycemia compared to older diabetes medications.

Central Nervous System Effects

Semaglutide crosses the blood-brain barrier and acts on GLP-1 receptors in the hypothalamus and brainstem, particularly the arcuate nucleus and the nucleus tractus solitarius. This central action produces:

• Reduced appetite and food cravings through modulation of hunger-signaling pathways
• Increased satiety signals that help patients feel full with smaller portions
• Decreased reward-driven eating by modulating dopaminergic pathways

Gastrointestinal Effects

Semaglutide slows gastric emptying, which contributes to prolonged feelings of fullness after meals. This delayed gastric transit is a significant contributor to the appetite reduction experienced by patients and is also responsible for some of the gastrointestinal side effects.

Metabolic Effects

Beyond direct weight and glucose effects, semaglutide influences lipid metabolism, reduces hepatic fat accumulation, and decreases systemic inflammation. Research from the STEP trials showed improvements in waist circumference, blood pressure, lipid profiles, and inflammatory markers such as C-reactive protein (CRP).

Evidence-Based Benefits of Semaglutide

The clinical evidence supporting semaglutide spans numerous large-scale randomized controlled trials. Key benefits include:

• Significant weight loss: Average of 14.9% body weight reduction in the STEP 1 trial; up to 17.4% in STEP 5 (2-year data). Approximately one-third of participants lost more than 20% of their body weight.
• Improved glycemic control: HbA1c reductions of 1.5–2.0 percentage points in type 2 diabetes patients, with many achieving target HbA1c levels below 7%.
• Cardiovascular risk reduction: The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) including heart attack, stroke, and cardiovascular death.
• Blood pressure improvement: Systolic blood pressure reductions of 4–6 mmHg observed across STEP trials.
• Lipid profile improvement: Reductions in triglycerides, LDL cholesterol, and improvements in HDL cholesterol.
• Reduction in liver fat: Emerging data suggests significant reductions in hepatic steatosis, with potential benefits for non-alcoholic fatty liver disease (NAFLD/MASH).
• Improved quality of life: Patient-reported outcomes show improvements in physical functioning, mobility, and overall well-being.
• Reduced inflammation: Decreases in CRP and other inflammatory biomarkers observed across multiple studies.

The STEP program (trials 1 through 5 and additional sub-studies) provides one of the most robust evidence bases for any anti-obesity medication in history, with over 10,000 participants studied across diverse populations.

Key Clinical Trials

STEP 1 (Wilding et al., NEJM, 2021): 1,961 participants with obesity without diabetes. Semaglutide 2.4 mg weekly produced 14.9% mean weight loss vs. 2.4% with placebo over 68 weeks. 86.4% achieved ≥5% weight loss; 69.1% achieved ≥10%.

STEP 2 (Davies et al., Lancet, 2021): 1,210 participants with obesity and type 2 diabetes. Semaglutide 2.4 mg produced 9.6% mean weight loss vs. 3.4% with placebo, with significant HbA1c improvements.

STEP 3 (Wadden et al., JAMA, 2021): 611 participants combined semaglutide with intensive behavioral therapy. Mean weight loss of 16.0% vs. 5.7% with placebo plus behavioral therapy.

STEP 5 (Garvey et al., Nature Medicine, 2022): 304 participants over 104 weeks. Sustained 15.2% mean weight loss at 2 years, demonstrating long-term durability.

SELECT Trial (Lincoff et al., NEJM, 2023): 17,604 participants with established cardiovascular disease and overweight/obesity but without diabetes. Semaglutide reduced MACE by 20% (HR 0.80, 95% CI 0.72–0.90). This trial established semaglutide's cardiovascular benefit independent of diabetes.

"Semaglutide represents a paradigm shift in obesity medicine, achieving weight loss outcomes previously only seen with bariatric surgery." — Obesity Medicine Association position statement

Additional studies including STEP-TEENS (adolescent obesity), FLOW (chronic kidney disease), and SOUL (ongoing cardiovascular outcomes) continue to expand the evidence base for semaglutide across diverse clinical populations.

Typical Dosing Protocol

Semaglutide for weight management (Wegovy) follows a standardized dose escalation schedule to minimize gastrointestinal side effects:

• Weeks 1–4: 0.25 mg subcutaneously once weekly
• Weeks 5–8: 0.5 mg subcutaneously once weekly
• Weeks 9–12: 1.0 mg subcutaneously once weekly
• Weeks 13–16: 1.7 mg subcutaneously once weekly
• Week 17 onward: 2.4 mg subcutaneously once weekly (maintenance dose)

For type 2 diabetes (Ozempic), the target dose is typically 0.5 mg, 1.0 mg, or 2.0 mg once weekly, depending on glycemic response.

Administration: Injected subcutaneously in the abdomen, thigh, or upper arm. The injection day can be any day of the week, and should be given at approximately the same time. Can be administered with or without meals.

Clinical note: Some providers may adjust the escalation timeline based on individual tolerability. If significant GI side effects occur, delaying dose escalation by 2–4 weeks is common practice. Patients who cannot tolerate the 2.4 mg dose may be maintained at 1.7 mg.